QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: Life Sciences Tools & Services
- Symbol: NASDAQ:QGEN
- CUSIP: N7248210
- Web: www.qiagen.com
- Market Cap: $7.35 billion
- Outstanding Shares: 228,233,000
- 50 Day Moving Avg: $31.87
- 200 Day Moving Avg: $31.77
- 52 Week Range: $24.89 - $35.26
Sales & Book Value:
- Trailing P/E Ratio: 98.44
- Foreward P/E Ratio: 23.84
- P/E Growth: 1.92
- Annual Revenue: $1.36 billion
- Price / Sales: 5.40
- Book Value: $10.98 per share
- Price / Book: 2.93
- EBIDTA: $443.36 million
- Net Margins: 5.44%
- Return on Equity: 11.04%
- Return on Assets: 6.53%
- Debt-to-Equity Ratio: 0.55%
- Current Ratio: 3.85%
- Quick Ratio: 3.34%
- Average Volume: 901,241 shs.
- Beta: 1.15
- Short Ratio: 3.51
Frequently Asked Questions for Qiagen N.V. (NASDAQ:QGEN)
What is Qiagen N.V.'s stock symbol?
Qiagen N.V. trades on the NASDAQ under the ticker symbol "QGEN."
How were Qiagen N.V.'s earnings last quarter?
Qiagen N.V. (NASDAQ:QGEN) issued its quarterly earnings data on Thursday, July, 27th. The company reported $0.30 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.28 by $0.02. The business earned $349 million during the quarter, compared to the consensus estimate of $353.09 million. Qiagen N.V. had a return on equity of 11.04% and a net margin of 5.44%. The business's revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.24 earnings per share. View Qiagen N.V.'s Earnings History.
When will Qiagen N.V. make its next earnings announcement?
What guidance has Qiagen N.V. issued on next quarter's earnings?
Qiagen N.V. updated its FY17 earnings guidance on Thursday, July, 27th. The company provided EPS guidance of $1.25-1.27 for the period, compared to the Thomson Reuters consensus estimate of $1.25.
Where is Qiagen N.V.'s stock going? Where will Qiagen N.V.'s stock price be in 2017?
12 analysts have issued 12-month price targets for Qiagen N.V.'s stock. Their forecasts range from $27.00 to $37.00. On average, they anticipate Qiagen N.V.'s stock price to reach $32.56 in the next twelve months. View Analyst Ratings for Qiagen N.V..
Who are some of Qiagen N.V.'s key competitors?
Some companies that are related to Qiagen N.V. include Alnylam Pharmaceuticals (ALNY), Alkermes PLC (ALKS), Seattle Genetics (SGEN), Ionis Pharmaceuticals (IONS), Icon Plc (ICLR), Exact Sciences Corporation (EXAS), Galapagos NV (GLPG), Charles River Laboratories International (CRL), United Therapeutics Corporation (UTHR), PRA Health Sciences (PRAH), ACADIA Pharmaceuticals (ACAD), Bio-Techne Corp (TECH), PAREXEL International Corporation (PRXL), FibroGen (FGEN), Puma Biotechnology (PBYI), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX) and Portola Pharmaceuticals (PTLA).
Who are Qiagen N.V.'s key executives?
Qiagen N.V.'s management team includes the folowing people:
- Manfred E. Karobath, Chairman of the Supervisory Board
- Peer M. Schatz, Chief Executive Officer, Managing Director
- Roland Sackers, Chief Financial Officer
- Thomas Schweins, Senior Vice President - Human Resources, Strategy & Marketing Services
- Thierry Bernard, Senior Vice President - Molecular Diagnostics Business Area
- Laura Furmanski, Senior Vice President - Bioinformatics Business Area
- Douglas Liu, Senior Vice President - Global Operations
- Manuel O. Mendez, Senior Vice President - Global Commercial Operations
- Stephane Bancel, Independent Supervisory Director
- Hakan Bjorklund, Supervisory Board Director
Who owns Qiagen N.V. stock?
Qiagen N.V.'s stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (8.94%), BlackRock Inc. (3.59%), Baillie Gifford & Co. (3.14%), Vanguard Group Inc. (2.65%), Johnston Asset Management LLC (1.59%) and Manning & Napier Advisors LLC (1.34%). View Institutional Ownership Trends for Qiagen N.V..
Who sold Qiagen N.V. stock? Who is selling Qiagen N.V. stock?
Qiagen N.V.'s stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Balyasny Asset Management LLC, Douglas Lane & Associates LLC, Manning & Napier Advisors LLC, Harris Associates L P, AXA, Canada Pension Plan Investment Board and Platinum Investment Management Ltd.. View Insider Buying and Selling for Qiagen N.V..
Who bought Qiagen N.V. stock? Who is buying Qiagen N.V. stock?
Qiagen N.V.'s stock was acquired by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Los Angeles Capital Management & Equity Research Inc., WINTON GROUP Ltd, Exane Asset Management, Atlanta Capital Management Co. L L C, Vanguard Group Inc., BlackRock Inc. and Neuberger Berman Group LLC. View Insider Buying and Selling for Qiagen N.V..
How do I buy Qiagen N.V. stock?
Shares of Qiagen N.V. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Qiagen N.V.'s stock price today?
MarketBeat Community Rating for Qiagen N.V. (NASDAQ QGEN)MarketBeat's community ratings are surveys of what our community members think about Qiagen N.V. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Qiagen N.V. stock can currently be purchased for approximately $32.19.
Consensus Ratings for Qiagen N.V. (NASDAQ:QGEN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||7 Hold Ratings, 5 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.42)|
|Consensus Price Target: ||$32.56 (1.16% upside)|
Analysts' Ratings History for Qiagen N.V. (NASDAQ:QGEN)
(Data available from 9/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/28/2017||DZ Bank AG||Reiterated Rating||Neutral||Low|
|8/17/2017||Commerzbank Ag||Reiterated Rating||Buy||Low|
|8/14/2017||Cowen and Company||Reiterated Rating||Hold||$33.00||Low|
|8/1/2017||Independent Research GmbH||Upgrade||Sell -> Hold||Low|
|7/31/2017||Jefferies Group LLC||Reiterated Rating||Hold||$25.00 -> $28.00||Low|
|7/31/2017||Deutsche Bank AG||Reiterated Rating||Buy||Low|
|7/21/2017||Bank of America Corporation||Reiterated Rating||Neutral||$33.00 -> $36.00||Low|
|7/17/2017||Barclays PLC||Reiterated Rating||Overweight||$33.00 -> $37.00||Low|
|7/13/2017||Wells Fargo & Company||Reiterated Rating||Market Perform||$28.00 -> $31.00||Low|
|7/10/2017||Morgan Stanley||Reiterated Rating||Overweight||$36.00 -> $37.00||Low|
|5/4/2017||Evercore ISI||Boost Price Target||Outperform||$30.00 -> $31.50||High|
|11/3/2016||J P Morgan Chase & Co||Reiterated Rating||Hold||$27.00||N/A|
|8/1/2016||HSBC Holdings plc||Upgrade||Hold -> Buy||N/A|
|8/1/2016||Mizuho||Boost Price Target||Neutral||$22.00 -> $25.00||N/A|
|7/25/2016||Piper Jaffray Companies||Reiterated Rating||Neutral||$23.00||N/A|
|3/15/2016||Citigroup Inc.||Lower Price Target||Neutral||$28.00 -> $25.00||N/A|
|11/12/2015||Stifel Nicolaus||Initiated Coverage||Hold||N/A|
|10/30/2015||Goldman Sachs Group, Inc. (The)||Lower Price Target||$22.00 -> $21.00||N/A|
|10/29/2015||Wedbush||Lower Price Target||Neutral||$21.00 -> $20.00||N/A|
Earnings History for Qiagen N.V. (NASDAQ:QGEN)Earnings History by Quarter for Qiagen N.V. (NASDAQ QGEN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/27/2017||6/30/2017||$0.28||$0.30||$353.09 million||$349.00 million||View||N/A|
|2/1/2017||Q416||$0.34||$0.39||$372.70 million||$366.50 million||View||Listen|
|11/2/2016||Q316||$0.28||$0.29||$335.46 million||$338.70 million||View||N/A|
|7/28/2016||Q216||$0.23||$0.24||$326.73 million||$334.40 million||View||N/A|
|4/27/2016||Q116||$0.19||$0.19||$295.76 million||$298.40 million||View||N/A|
|2/2/2016||Q415||$0.32||$0.33||$354.47 million||$349.00 million||View||N/A|
|10/28/2015||Q315||$0.28||$0.27||$323.50 million||$314.60 million||View||Listen|
|7/29/2015||Q215||$0.25||$0.26||$319.43 million||$319.50 million||View||Listen|
|5/7/2015||Q115||$0.22||$0.22||$304.60 million||$298.70 million||View||N/A|
|1/28/2015||Q414||$0.30||$0.25||$367.82 million||$360.80 million||View||N/A|
|10/29/2014||Q3||$0.27||$0.27||$337.00 million||$336.80 million||View||N/A|
|7/29/2014||Q214||$0.25||$0.26||$330.76 million||$331.20 million||View||N/A|
|5/7/2014||Q114||$0.22||$0.22||$317.09 million||$317.40 million||View||N/A|
|1/29/2014||Q413||$0.34||$0.36||$365.52 million||$362.60 million||View||N/A|
|10/29/2013||Q313||$0.25||$0.28||$320.37 million||$323.80 million||View||N/A|
|7/30/2013||Q213||$0.24||$0.27||$311.75 million||$316.40 million||View||N/A|
|4/29/2013||Q113||$0.23||$0.23||$305.50 million||$303.60 million||View||N/A|
|1/29/2013||Q412||$0.31||$0.34||$327.80 million||$346.50 million||View||N/A|
|11/5/2012||Q312||$0.24||$0.26||$303.79 million||$304.30 million||View||N/A|
Earnings Estimates for Qiagen N.V. (NASDAQ:QGEN)
2017 EPS Consensus Estimate: $1.20
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Qiagen N.V. (NASDAQ:QGEN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Qiagen N.V. (NASDAQ:QGEN)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Qiagen N.V. (NASDAQ:QGEN)
Latest Headlines for Qiagen N.V. (NASDAQ:QGEN)
Qiagen N.V. (QGEN) Chart for Saturday, September, 23, 2017